Detalhe da pesquisa
1.
Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.
Oncologist
; 29(2): e224-e236, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37682776
2.
Non-Small Cell Lung Cancer, Version 4.2024.
J Natl Compr Canc Netw
; 22(4): 249-274, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754467
3.
Mesothelioma: Pleural, Version 1.2024.
J Natl Compr Canc Netw
; 22(2): 72-81, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38503043
4.
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
J Natl Compr Canc Netw
; 21(4): 340-350, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015337
5.
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(9): 961-979, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37673108
6.
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(5): 497-530, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545176
7.
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Cancer
; 126(14): 3219-3228, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365229
8.
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
Curr Treat Options Oncol
; 21(7): 60, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32588244
9.
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.
Oncologist
; 24(10): 1305-1308, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31391294
10.
Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.
Cancer
; 124(3): 521-529, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29044458
11.
Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Oncologist
; 23(7): 764-e86, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29540603
12.
New and emerging developments in extensive-stage small cell lung cancer therapeutics.
Curr Opin Oncol
; 28(2): 97-103, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26844984
13.
Multidisciplinary Care.
Cancer Treat Res
; 170: 285-300, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27535399
14.
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
Immunopharmacol Immunotoxicol
; 36(2): 182-6, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24494587
15.
Targeting MEK in non-small cell lung cancer.
Curr Probl Cancer
; 49: 101065, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341356
16.
CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report.
JCO Precis Oncol
; 8: e2300677, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603654
17.
Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 30(5): 998-1008, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127300
18.
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
J Thorac Oncol
; 19(3): 500-506, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38012986
19.
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Nat Commun
; 15(1): 3741, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702301
20.
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.
Invest New Drugs
; 31(6): 1587-91, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24013936